Thermo Fisher Scientific has assumed operational responsibility for a new biologics manufacturing site in Lengnau, Switzerland as part of its strategic partnership with CSL announced last year. The Lengnau site will become part of Thermo Fisher's global biologics manufacturing network, and approximately 200 employees will join Thermo Fisher. 

The Lengnau site is a 1.5 million square-foot facility that will leverage highly flexible bioproduction technologies, including both single-use and stainless steel with up to 12,500L bioreactor capacity. This will provide biopharma companies with a pathway from development to large-scale production as manufacturing needs evolve. 

"We are excited to add the new Lengnau site to our global biologics manufacturing network and we are thrilled to welcome more than 200 new colleagues to Thermo Fisher," said Michel Lagarde, Executive VP, Thermo Fisher Scientific. "Through our partnership with CSL, this site further strengthens our unique customer value proposition to leverage our scale and depth of capabilities for pharma and biotech customers. With the addition of new high-volume stainless-steel capabilities in Lengnau, we are enabling our customers to start their projects with us and stay with us as their manufacturing requirements grow."

Following completion of site construction in 2022, Thermo Fisher will initially support manufacturing of CSL's next-generation recombinant factor IX product Idelvion for patients with hemophilia B. Over time, Thermo Fisher plans to expand the use of the site to include additional biopharma customers.

The Lengnau site is an important expansion of Thermo Fisher's biologics manufacturing network that includes Princeton, NJ and St Louis, MO, USA; Groningen, NL; Brisbane, AU; and Hangzhou, China.